Overactive Bladder

OAB drugs draw flak for allegedly weak efficacy

By

An FDA advisory panel endorsed Astellas' overactive bladder medication mirabegron April 6, but not everyone is on board.

DDR on DTC: Toviaz vs. Vesicare

DDR on DTC: Toviaz vs. Vesicare

Two brands are fighting for attention from OAB sufferers: GSK-Astellas's Vesicare and Pfizer's Toviaz. Their DTC approaches couldn't be more different.

Email Newsletters